Depomed wins FDA OK of gabapentin drug, but will Abbott launch?
This article was originally published in Scrip
Executive Summary
The FDA late 28 January cleared Depomed's Gralise, a once-daily oral formulation of gabapentin, for marketing as a treatment for postherpetic neuralgia (PHN), the pain that follows a bout of shingles.